SWTX Similar Chart Price Prediction
The price of SWTX is predicted to go up -23.67%, based on the high correlation periods with SGMO. The similarity of these two price pattern on the periods is 90.92%.
SWTX
SGMO
Down: -23.67%Similarity: 90.92%
SWTX Revenue Forecast
SWTX EPS Forecast
SWTX FAQs
What is bull’s view on SWTX?
What is bear's view on SWTX?
What is SWTX revenue forecast for next quarter？
What is SWTX eps forecast for next quarter？
SWTX Analyst's Forecast
Cory Kasimov
Evercore ISI Group
Buy
2024-11-20
Price Target
$60
Upside
+60.26%
Evercore ISI analyst Cory Kasimov initiated coverage of SpringWorks Therapeutics with an Outperform rating and $60 price target. SpringWorks looks "well positioned" based on its first-in-class approved therapy for a rare oncology indication, Ogsiveo, the first and only FDA approved tx for desmoid tumors, and "the near-term potential to become a two-product story" with Mirdametinib, for which the firm sees a potential Q1 of 2025 approval, the analyst tells investors. Shares bouncing post a slight Q3 miss suggests "this is an attractive entry point with solid, underlying market dynamics carrying greater weight," the analyst added.
